Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-312024-01-01falseNo description of principal activity54truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 05982368 2024-01-01 2024-12-31 05982368 2023-01-01 2023-12-31 05982368 2024-12-31 05982368 2023-12-31 05982368 c:Director1 2024-01-01 2024-12-31 05982368 d:MotorVehicles 2024-01-01 2024-12-31 05982368 d:MotorVehicles 2024-12-31 05982368 d:MotorVehicles 2023-12-31 05982368 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 05982368 d:FurnitureFittings 2024-01-01 2024-12-31 05982368 d:FurnitureFittings 2024-12-31 05982368 d:FurnitureFittings 2023-12-31 05982368 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 05982368 d:OfficeEquipment 2024-01-01 2024-12-31 05982368 d:OfficeEquipment 2024-12-31 05982368 d:OfficeEquipment 2023-12-31 05982368 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 05982368 d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 05982368 d:CurrentFinancialInstruments 2024-12-31 05982368 d:CurrentFinancialInstruments 2023-12-31 05982368 d:Non-currentFinancialInstruments 2024-12-31 05982368 d:Non-currentFinancialInstruments 2023-12-31 05982368 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 05982368 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 05982368 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 05982368 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 05982368 d:ShareCapital 2024-12-31 05982368 d:ShareCapital 2023-12-31 05982368 d:SharePremium 2024-12-31 05982368 d:SharePremium 2023-12-31 05982368 d:RevaluationReserve 2024-12-31 05982368 d:RevaluationReserve 2023-12-31 05982368 d:RetainedEarningsAccumulatedLosses 2024-12-31 05982368 d:RetainedEarningsAccumulatedLosses 2023-12-31 05982368 c:FRS102 2024-01-01 2024-12-31 05982368 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 05982368 c:FullAccounts 2024-01-01 2024-12-31 05982368 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 05982368 2 2024-01-01 2024-12-31 05982368 5 2024-01-01 2024-12-31 05982368 6 2024-01-01 2024-12-31 05982368 e:Euro 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Registered number: 05982368









MODERN MEDICAL SYSTEMS LIMITED








FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

 
MODERN MEDICAL SYSTEMS LIMITED
REGISTERED NUMBER: 05982368

BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
2023
Note

Fixed assets
  

Tangible assets
 4 
44,389
69,119

Investments
  
-
556,291

  
44,389
625,410

Current assets
  

Stocks
  
-
182,938

Debtors
  
8,404,335
10,228,160

Cash at bank and in hand
  
4,300,504
5,954,428

  
12,704,839
16,365,526

Creditors: amounts falling due within one year
 7 
(433,338)
(888,620)

Net current assets
  
 
 
12,271,501
 
 
15,476,906

Total assets less current liabilities
  
12,315,890
16,102,316

Creditors: amounts falling due after more than one year
  
(4,850,828)
(7,900,133)

Net assets
  
7,465,062
8,202,183


Capital and reserves
  

Called up share capital 
  
2,748
2,748

Share premium account
  
312,580
312,580

Other reserves
  
255,517
255,517

Profit and loss account
  
6,894,217
7,631,338

  
7,465,062
8,202,183


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions
Page 1

 
MODERN MEDICAL SYSTEMS LIMITED
REGISTERED NUMBER: 05982368
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 12 January 2026.




Elena Dzhumanova
Director

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
MODERN MEDICAL SYSTEMS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

Modern Medical Systems Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page. 
The presentation currency of the financial statements is the Euro (€). 
The company's trade is currently predominately being conducted in Euros, which is now considered to be the functional currency of the company. Consequently, to minimise unnecessary foreign exchange differences appearing in the company's financial statements and to present a fairer view of the company's financial position and results, it was decided to prepare the financial statements for the year under review and those of subsequent accounting periods in Euros. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

Page 3

 
MODERN MEDICAL SYSTEMS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
MODERN MEDICAL SYSTEMS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)


2.5
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles
-
20%
on cost
Fixtures and fittings
-
20%
on cost
Office equipment
-
20%
on cost

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.6

Revaluation of tangible fixed assets

Individual freehold and leasehold properties are carried at current year value at fair value at the date of the revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. Revaluations are undertaken with sufficient regularity to ensure the carrying amount does not differ materially from that which would be determined using fair value at the balance sheet date.
Fair values are determined from market based evidence normally undertaken by professionally qualified valuers.

Revaluation gains and losses are recognised in other comprehensive income unless losses exceed the previously recognised gains or reflect a clear consumption of economic benefits, in which case the excess losses are recognised in profit or loss.

 
2.7

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of Comprehensive Income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

Page 5

 
MODERN MEDICAL SYSTEMS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.8

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.9

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.10

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.12

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 5 (2023 - 4).

Page 6

 
MODERN MEDICAL SYSTEMS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

4.


Tangible fixed assets





Motor vehicles
Fixtures and fittings
Office equipment
Total




Cost or valuation


At 1 January 2024
162,500
-
11,620
174,120


Additions
-
150
-
150



At 31 December 2024

162,500
150
11,620
174,270



Depreciation


At 1 January 2024
98,358
-
6,643
105,001


Charge for the year on owned assets
24,880
-
-
24,880



At 31 December 2024

123,238
-
6,643
129,881



Net book value



At 31 December 2024
39,262
150
4,977
44,389



At 31 December 2023
64,142
-
4,977
69,119


5.


Debtors

2024
2023

Due after more than one year

Other debtors
1,968
1,968

Prepayments and accrued income
1,737
900

3,705
2,868

Due within one year

Trade debtors
8,376,438
10,224,786

Amounts owed by joint ventures and associated undertakings
23,891
-

Other debtors
301
506

8,404,335
10,228,160


Page 7

 
MODERN MEDICAL SYSTEMS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6.


Cash and cash equivalents

2024
2023

Cash at bank and in hand
4,300,504
5,954,428

4,300,504
5,954,428



7.


Creditors: Amounts falling due within one year

2024
2023

Trade creditors
284,180
726,409

Corporation tax
36,799
999

Other creditors
41,400
36,622

Accruals and deferred income
70,959
124,590

433,338
888,620



8.


Creditors: Amounts falling due after more than one year

2024
2023

Other creditors
4,850,828
7,900,133

4,850,828
7,900,133


Page 8